Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Colorado: - Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- Intermountain Health Platte Valley Hospital — Brighton, Colorado
- Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Saint Francis Cancer Center — Colorado Springs, Colorado
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Colorado: - St.Joseph Hospital- Cancer Centers of Colorado — Denver, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
- AHMG Hematology and Oncology — Parker, Colorado
- Cancer Care at CommonSpirit St. Anthony North Hospital — Westminster, Colorado
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Colorado: - AdventHealth Medical Group Hematology and Oncology — Denver, Colorado
- Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Colorado: - Research Site — Aurora, Colorado
- Research Site — Denver, Colorado
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Colorado: - Rocky Mountain Cancer Centers — Littleton, Colorado
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Colorado: - Intermountain Health Cancer Center Saint Joseph ( Site 0062) — Denver, Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006) — Denver, Colorado
- Intermountain Health St. Mary's Regional Hospital ( Site 0054) — Grand Junction, Colorado
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Colorado: - University of Colorado-Cancer Center-PPDS — Aurora, Colorado
- Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Academic/Other
In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commo…
Sponsor: Rocky Mountain Cancer Centers
NCT ID: NCT01185132
Sites in Colorado: - Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado
- Rocky Mountain Cancer Centers - Boulder — Boulder, Colorado
- Rocky Mountain Cancer Centers - Lakewood — Lakewood, Colorado
- Rocky Mountain Cancer Centers - Littleton — Littleton, Colorado
- Rocky Mountain Cancer Centers - Thornton — Thornton, Colorado
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Medical Center of the Rockies — Loveland, Colorado
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Colorado: - University of Colorado School of Medicine — Aurora, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Colorado: - Rocky Mountain Cancer Center - Longmont — Longmont, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 2 Recruiting Academic/Other
This study investigates the efficacy of a telehealth exercise program designed specifically for rural cancer survivors with cancer-related fatigue (CRF). Small dried blood samples and measures of physical function will be collected through…
Sponsor: University of Colorado, Denver
NCT ID: NCT07001241
Sites in Colorado: - University of Colorado Anschutz Medical Campus — Aurora, Colorado
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Colorado: - SCRI at HealthOne — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
NCT ID: NCT06908928
Sites in Colorado: - Anschutz Medical Center — Aurora, Colorado